We are currently establishing a preclinical development plan for Allocell.
Allogenic cell-therapy treatment for severe chronic damage to the heart.
We anticipate that Allocell will be similar to MyoCell, except that the myoblast cells to be injected will be taken from third party donors. Like MyoCell, we hope to demonstrate that allogenic myoblasts are a safe and effective treatment of severe heart damage. We anticipate that Allocell may be administered in conjunction with immunosuppressive drugs to reduce the risk of tissue rejection. We are exploring the storage life of myoblast cells and the feasibility of maintaining an inventory of Allocell from which interventional cardiologists can select to perform the myoblast implantation procedure.
We believe our license agreement with Dr. Law and Cell Transplants International provides us a conditionally exclusive license in the United States to certain patents that include claims we believe cover the use of cultured allogenic myoblast cells for the administration to diseased muscle within the field of heart muscle repair and angiogenesis.
We are currently establishing a preclinical development plan for Allocell.
Candidate |
Proposed Use or Indication |
Status/Phase |
||
|---|---|---|---|---|
| Allocell | Allogenic cell-therapy treatment for severe chronic damage to the heart. | Preclinical |
||
| Comments: Preclinical development by Bioheart. | ||||